John D Haley

Summary

Affiliation: OSI Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells
    April Thelemann
    OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Mol Cell Proteomics 4:356-76. 2005
  2. pmc Identification and characterization of mechanistically distinct inducers of gamma-globin transcription
    John D Haley
    OSI Pharmaceuticals Inc, Farmingdale, NY 11735, USA
    Biochem Pharmacol 66:1755-68. 2003
  3. pmc A systems view of epithelial-mesenchymal transition signaling states
    Stuart Thomson
    Translational Research, OSI Pharmaceuticals Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 28:137-55. 2011
  4. doi request reprint Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
    Stuart Thomson
    Department of Translational Research, OSI Pharmaceuticals Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 25:843-54. 2008
  5. ncbi request reprint Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
    Elizabeth Buck
    OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 6:532-41. 2007
  6. ncbi request reprint Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
    Elizabeth Buck
    OSI Pharmaceuticals, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2676-84. 2006
  7. doi request reprint Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
    Elizabeth Buck
    Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale, New York 11735, USA
    Cancer Res 68:8322-32. 2008
  8. ncbi request reprint Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
    Elizabeth Buck
    Department of Translational Research, OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2051-9. 2006
  9. ncbi request reprint Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
    Stuart Thomson
    Departments of Translational Research and Oncology Research, OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Cancer Res 65:9455-62. 2005
  10. pmc Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
    Sharon Barr
    OSI Pharmaceuticals Inc, 1 Bioscience Park Dr, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 25:685-93. 2008

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells
    April Thelemann
    OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Mol Cell Proteomics 4:356-76. 2005
    ..The functional interactions between IGF-1 receptor, lysophosphatidic acid (LPA) signaling, and EGF receptor were observed, both direct and/or indirectly on phospho-Akt, phospho-Erk1/2, and phospho-ribosomal S6...
  2. pmc Identification and characterization of mechanistically distinct inducers of gamma-globin transcription
    John D Haley
    OSI Pharmaceuticals Inc, Farmingdale, NY 11735, USA
    Biochem Pharmacol 66:1755-68. 2003
    ..This screening methodology successfully identifies active compounds for further mechanistic and preclinical evaluation as potential therapeutic agents for sickle cell anemia...
  3. pmc A systems view of epithelial-mesenchymal transition signaling states
    Stuart Thomson
    Translational Research, OSI Pharmaceuticals Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 28:137-55. 2011
    ..Correlation to stem cell, EMT, invasion and metastasis datasets revealed the greatest similarity with normal and cancerous breast stem cell populations, CD49f(hi)/EpCAM(-/lo) and CD44(hi)/CD24(lo), respectively...
  4. doi request reprint Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
    Stuart Thomson
    Department of Translational Research, OSI Pharmaceuticals Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 25:843-54. 2008
    ..The findings of kinase switching and acquired PDGFR and FGFR signaling suggest investigation of new inhibitor combinations to target NSCLC metastases...
  5. ncbi request reprint Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
    Elizabeth Buck
    OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 6:532-41. 2007
    ....
  6. ncbi request reprint Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
    Elizabeth Buck
    OSI Pharmaceuticals, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2676-84. 2006
    ..These results suggest that combining rapamycin with erlotinib might be clinically useful to enhance response to erlotinib...
  7. doi request reprint Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors
    Elizabeth Buck
    Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale, New York 11735, USA
    Cancer Res 68:8322-32. 2008
    ..Collectively, these data show that resistance to inhibition of MEK, mTOR, and EGFR is associated with enhanced IGF-IR-directed Akt signaling, where all affect feedback loops converging at the level of IRS-1...
  8. ncbi request reprint Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
    Elizabeth Buck
    Department of Translational Research, OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11787, USA
    Mol Cancer Ther 5:2051-9. 2006
    ..These studies suggest that HER-3 could be used as a biomarker to select patients who are most likely to respond to erlotinib therapy...
  9. ncbi request reprint Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
    Stuart Thomson
    Departments of Translational Research and Oncology Research, OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Cancer Res 65:9455-62. 2005
    ..These data suggest that EMT may be a general biological switch rendering non-small cell lung tumors sensitive or insensitive to EGFR inhibition...
  10. pmc Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
    Sharon Barr
    OSI Pharmaceuticals Inc, 1 Bioscience Park Dr, Farmingdale, NY 11735, USA
    Clin Exp Metastasis 25:685-93. 2008
    ..The interaction between EGFR and the multiple signaling nodes which regulate EMT suggest that the combination of an EGFR inhibitor and other molecular targeted agents may offer a novel approach to controlling metastasis...
  11. ncbi request reprint Peptide, domain, and DNA affinity selection in the identification and quantitation of proteins from complex biological samples
    Filippo Petti
    Translational Research, OSI Oncology, Farmingdale, NY 11735, USA
    Anal Biochem 356:1-11. 2006
  12. ncbi request reprint Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930
    Filippo Petti
    OSI Pharmaceuticals, Inc, 1 Bioscience Park Drive, Farmingdale, NY 11735, USA
    Mol Cancer Ther 4:1186-97. 2005
    ....
  13. ncbi request reprint Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
    Kendall D Carey
    Department of Translational Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Res 66:8163-71. 2006
    ..These findings suggest that EGFR somatic mutations directly influence both erlotinib sensitivity and cellular transformation...